While Eli Lilly’s LLY top-line continues to touch new sky highs thanks to its blockbuster GLP-1 medicines — Mounjaro (for ...

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for ...

US pharma major Eli Lilly today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase III clinical trials ...

Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its latest attempt to fend off competition from copies of its weight-loss drug.

RBC Capital Markets analysts believe Eli Lilly’s upcoming TRAILBLAZER-3 trial data on Kisunla could unlock a vast, largely untapped segment of the Alzheimer’s treatment market and pave the way for ...

Eli Lilly (NYSE:LLY), a major pharmaceutical company listed on the S&P 500 and NYSE Composite, continues to attract attention with developments across its legal, research, and expansion efforts. As ...

Eli Lilly shares fall as competitor Novo notches coverage win for obesity ... Novo’s weight loss treatment Wegovy will be the preferred GLP-1 medicine on its largest commercial formularies, ...

Verve Therapeutics VERV signed a definitive agreement with pharma bigwig Eli Lilly LLY. Per the terms, the pharma giant will acquire all outstanding shares of VERV for $10.50 per share in cash ...

Eli Lilly’s acquisition of SiteOne Therapeutics comes ahead of Phase 2 testing of the startup’s lead drug candidate, which blocks the NaV1.8 sodium channel to treat pain. This target has ...

Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion, the drugmaker’s latest investment in an experimental medicine that could fuel its long-term ...